In the original article, there was a mistake in Figure 2. Wrong microscopy photographs were included in the Sham and Mif/Tz 3-week groups. The corrected Figure 2 appears below.
Figure 2
The authors apologize for this mistake and state that this does not change the article’s scientific discussion and conclusions in any way. The original article has been updated.
Summary
Keywords
glioblastoma, temozolomide, mifepristone, drug resistance, angiogenesis, P-gp
Citation
Llaguno-Munive M, León-Zetina S, Vazquez-Lopez I, Ramos-Godinez MP, Medina LA and Garcia-Lopez P (2021) Corrigendum: Mifepristone as a Potential Therapy to Reduce Angiogenesis and P-Glycoprotein Associated With Glioblastoma Resistance to Temozolomide. Front. Oncol. 11:675806. doi: 10.3389/fonc.2021.675806
Received
03 March 2021
Accepted
04 March 2021
Published
22 March 2021
Approved by
Frontiers Editorial Office, Frontiers Media SA, Switzerland
Volume
11 - 2021
Updates
Copyright
© 2021 Llaguno-Munive, León-Zetina, Vazquez-Lopez, Ramos-Godinez, Medina and Garcia-Lopez.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Patricia Garcia-Lopez, pgarcia_lopez@yahoo.com.mx
This article was submitted to Molecular and Cellular Oncology, a section of the journal Frontiers in Oncology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.